BladderCell

BladderCell is a biotechnology company focused on developing innovative therapeutics for the treatment of bladder cancer. Founded as a spin-out from the University of California, Irvine, the company leverages the research of Dr. Xiaolin Zi to target molecular pathways critical to tumor progression, specifically the Wnt/beta-catenin signaling pathway. BladderCell's pipeline includes both small molecule inhibitors and novel cell-based immunotherapies designed to address the high recurrence rates and limited treatment options for patients with non-muscle invasive and muscle-invasive bladder cancer. The company has received significant support from the National Cancer Institute through the Small Business Innovation Research (SBIR) program to advance its lead candidates toward clinical trials. BladderCell aims to provide more effective, targeted, and less toxic alternatives to current standard-of-care treatments.